Top

Published in:

01-10-2013 | Research Article

Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk

Authors: Hongtuan Zhang, Andi Wang, Hui Ma, Yong Xu

Published in: Tumor Biology | Issue 5/2013

Abstract

Epidemiological studies investigating the association between the insulin receptor substrate 1 (IRS1) gene Gly972Arg (rs1801278) polymorphism and various carcinomas risk reported conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. A comprehensive search was conducted to identify all eligible studies of IRS1 Gly972Arg polymorphism and cancer risk. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of the associations. A total of 16 independent studies, including 11,776 cases and 11,654 controls, were identified. When all studies were pooled, we found a significant association between IRS1 Gly972Arg polymorphism and increased cancer risk under dominant model (OR = 1.16, 95 %CI = 1.04–1.30, P = 0.007) and allelic model (OR = 1.16, 95 %CI = 1.02–1.30, P = 0.02). In subgroup analysis based on cancer type, increased cancer risk was found in ovarian cancer (dominant: OR = 1.55, 95 %CI = 1.17–2.05, P = 0.002; allelic: OR = 1.55, 95 %CI = 1.19–2.01, P = 0.001), breast cancer (allelic: OR = 1.12, 95 %CI = 1.00–1.26, P = 0.05), and other cancers (allelic: OR = 1.31, 95 %CI = 1.00–1.71, P = 0.05). When stratified by study types, significant associations were observed in both cohort studies (dominant: OR = 1.25, 95 %CI = 1.06–1.47, P = 0.007; allelic: OR = 1.25, 95 %CI = 1.07–1.46, P = 0.005) and case–control studies (dominant: OR = 1.15, 95 %CI = 1.01–1.31, P = 0.04). In the subgroup analyses by ethnicity, significantly increased cancer risk was suggested among both Caucasians (dominant: OR = 1.13, 95 %CI = 1.02–1.26, P = 0.02; allelic: OR = 1.13, 95 %CI = 1.03–1.25, P = 0.01) and mixed population (dominant: OR = 1.22, 95 %CI = 1.01–1.46, P = 0.04). Our investigations demonstrate that IRS1 Gly972Arg polymorphism was associated with an increased risk of cancer, and additional well-designed studies are warranted to validate these findings.

Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006;17:viii15–23.CrossRefPubMed

Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4:850–60.CrossRefPubMed

Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143–53.CrossRefPubMed

Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–99.CrossRefPubMed

Shpakov AO, Pertseva MN. Structural and functional characterization of insulin receptor substrate proteins and the molecular mechanisms of their interaction with insulin superfamily tyrosine kinase receptors and effector proteins. Membr Cell Biol. 2000;13:455–84.PubMed

Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet. 1999;23:32–40.PubMed

Waters SB, Pessin JE. Insulin receptor substrate 1 and 2 (IRS1 and IRS2): what a tangled web we weave. Trends Cell Biol. 1996;6:1–4.CrossRefPubMed

Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci. 2003;23:7084–92.PubMed

Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–28.CrossRefPubMed

10.

Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem. 1998;273:9994–10003.CrossRefPubMed

11.

Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001;15:2099–111.CrossRefPubMed

12.

Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene. 2000;19:5574–81.CrossRefPubMed

13.

Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, et al. The Gly972 Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest. 1999;104:357–64.PubMedCentralCrossRefPubMed

14.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

15.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed

16.

Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 2009;11:R76.PubMedCentralCrossRefPubMed

17.

Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, et al. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21:1362–70.PubMedCentralCrossRefPubMed

18.

Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W. Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer. 2005;115:148–54.CrossRefPubMed

19.

Samowitz WS, Wolff RK, Ma KN, Andersen K, Caan B, Slattery ML. Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. Mutat Res. 2006;595:117–24.CrossRefPubMed

20.

Slattery ML, Samowitz W, Curtin K, Ma KN, Hoffman M, Caan B, et al. Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1206–14.PubMed

21.

Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004;13:538–45.PubMed

22.

Slattery ML, Curtin K, Wolff R, Ma KN, Sweeney C, Murtaugh M, et al. PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control. 2006;17:239–49.CrossRefPubMed

23.

Dong X, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL, et al. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol. 2012;36:206–11.CrossRefPubMed

24.

Abulí A, Fernández-Rozadilla C, Alonso-Espinaco V, Muñoz J, Gonzalo V, Bessa X, et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Case–control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer. 2011;11:339.PubMedCentralCrossRefPubMed

25.

Saracevic A, Nikolac N, Reljic A, Simundic AM. Insulin receptor H1085H C > T and insulin receptor substrate 1 G972R polymorphisms and prostate cancer risk: a pilot study. Genet Test Mol Biomarkers. 2011;15:127–31.CrossRefPubMed

26.

Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, et al. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009;18:282–8.PubMedCentralCrossRefPubMed

27.

Ulybina IM, Imianitov EN, Vasil'ev DA, Bershteĭn LM. Polymorphism of glucose intolerance and insulin resistance susceptibility genes in oncological patients. Mol Biol (Mosk). 2008;42:947–56.CrossRef

28.

Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, et al. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate. 2008;68:1416–20.PubMedCentralCrossRefPubMed

29.

Pechlivanis S, Pardini B, Bermejo JL, Wagner K, Naccarati A, Vodickova L, et al. Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. Endocr Relat Cancer. 2007;14:733–40.CrossRefPubMed

30.

Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, Giuliano A, et al. Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat. 2007;104:197–209.CrossRefPubMed

31.

Li L, Cicek MS, Casey G, Witte JS. No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2462–3.CrossRefPubMed

32.

Neuhausen SL, Slattery ML, Garner CP, Ding YC, Hoffman M, Brothman AR. Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: strong association of IRS1 G972R variant and cancer risk. Prostate. 2005;64:168–74.CrossRefPubMed

33.

Wagner K, Hemminki K, Grzybowska E, Klaes R, Butkiewicz D, Pamula J, et al. The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer. Carcinogenesis. 2004;25:2473–8.CrossRefPubMed

34.

Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516–7.CrossRefPubMed

35.

Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20:439–44.CrossRefPubMed

36.

Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120–32.CrossRefPubMed

Title: Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk
Authors: Hongtuan Zhang
Andi Wang
Hui Ma
Yong Xu
Publication date: 01-10-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0855-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness

Ataxia–telangiectasia group D complementing gene (ATDC) upregulates matrix metalloproteinase 9 (MMP-9) to promote lung cancer cell invasion by activating ERK and JNK pathways

Overexpression of CRKL correlates with malignant cell proliferation in breast cancer

Glutathione S-transferase M1 null genotype is associated with increased risk of oral cancer in East Asians: a meta-analysis

Chromosomal imbalances exclusively detected in invasive front area are associated with poor outcome in laryngeal carcinomas from different anatomical sites

A comparative overview of general risk factors associated with the incidence of colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer